close
References
  1. Goldschmidt H, Mai EK, Nievergall E et al. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. Presented at: 62nd ASH Annual Meeting; December 11-14, 2021; Abstract 463.
  2. Costa LJ, Chhabra S, Callander NS et al. Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. Presented at: 62nd ASH Annual Meeting; December 11-14, 2021; Abstract 481.
  3. Dimopoulos MA, Quach H, Mateos MV, et al. Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Presented at: 62nd ASH Annual Meeting; December 5-8, 2020; Poster 2325.
  4. Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Presented at: 62nd ASH Annual Meeting; December 5-8, 2020; Abstract 412.
  5. Richardson PG. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and lowdose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Poster 8017.
  6. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study. Presented at: 2020 EHA Congress; June 11-21, 2020; Abstract LB2603.
  7. Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos et al. Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. Blood 2018; 132 (Supplement 1): 598.
  8. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 Feb 18;11(2):40.